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ABSTRACT 
As part of its Single Technology Appraisal process, the UK National Institute for Health and Care 
Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the clinical 
effectiveness and cost-effectiveness of ibrutinib for the treatment of relapsed or refractory (R/R) mantle 
cell lymphoma (MCL). The School of Health and Related Research Technology Assessment Group at 
the University of Sheffield was commissioned to act as the independent Evidence Review Group 
(ERG). The ERG produced a critical review of the evidence contained within WKHFRPSDQ\¶VVXEPLVVLRQ
to NICE. The clinical effectiveness evidence for ibrutinib included one randomised controlled trial 
(RCT) comparing ibrutinib versus temsirolimus (TEM) and two single-arm studies. 7KHFRPSDQ\¶V
indirect comparison of ibrutinib versus rituximab plus chemotherapy (R-chemo) produced a hazard 
ratio (HR) for progression-free survival (PFS) of 0.28. 7KH (5*¶V random effects network meta-
analysis (NMA) indicated that the treatment effect on PFS is highly uncertain (HR=0.27; 95% credible 
interval [CrI] 0.06, 1.26). 7KHFRPSDQ\¶V0DUNRYPRGHODVVHVVHGWKHFRVW-effectiveness of ibrutinib 
versus R-chemo for the treatment of R/R MCL from the perspective of the National Health Service 
(NHS) and Personal Social Services (PSS) over a lifetime horizon. Based on a re-run of tKHFRPSDQ\¶V
model by the ERG, the incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-chemo 
LQFOXGLQJ WKH FRPSDQ\¶V RULJLQDO 3DWLHQW $FFHVV 6FKHPH >PAS]) was expected to be £76,014 per 
quality-adjusted life year (QALY) gained. The ERG had several FRQFHUQV UHJDUGLQJ WKHFRPSDQ\¶V
model structure and the evidence used to inform its parameters. The ERG's preferred analysis, which 
XVHGWKH(5*¶VNMA and the observed Kaplan-Meier curve for time to ibrutinib discontinuation and 
which excluded long-term disutilities for R-chemo, produced ICERs of £63,340 per QALY gained for 
the overall R/R MCL population, and £44,711 per QALY gained for patients with one prior treatment. 
Following an updated PAS and consideration of evidence from a later data-cut of the RAY trial, the 
appraisal committee concluded that the most plausible ICER for the one prior treatment subgroup is 
OLNHO\WREHORZHUWKDQWKHFRPSDQ\¶VHVWLPDWHRISHU4$/<JDLQHG 7KHFRPSDQ\¶V,&(5IRU
the overall R/R MCL population was higher, at £62,650 per QALY gained. The committee 
recommended ibrutinib as an option for treating R/R MCL in adults, only if they have had only one 
previous line of therapy and the company provides ibrutinib with the discount agreed in the commercial 
access agreement with NHS England. 
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KEY POINTS FOR DECISION-MAKERS 
x The clinical evidence for ibrutinib was comprised of one randomised controlled trial of ibrutinib 
versus temsirolimus (RAY [MCL3001]) and two single-arm studies (PCYC1104 and SPARK 
[MCL2001]).  
x 7KH(5*¶VPDLQFRQFHUQVrelated to uncertainty surrounding the relative benefits of ibrutinib 
versus treatments currently used in UK clinical practice. 7KH(5*¶VH[SORUDWRU\UDQGRPHIIHFWV
network meta-analysis suggested a hazard ratio for PFS for ibrutinib versus rituximab plus 
chemotherapy of 0.27 (95% credible interval 0.06 to 1.23). 
x The ERG's preferred DQDO\VLVRIWKHFRPSDQ\¶VPRGHO(based on the original Patient Access 
Scheme [PAS]) resulted in an incremental cost-effectiveness ratio (ICER) of £63,340 per 
quality-adjusted life year (QALY) gained for the relapsed/refractory (R/R) mantle cell 
lymphoma (MCL) population and £44,711 per QALY gained for the one prior therapy 
subgroup.  
x The committee concluded that the most plausible ICER for the one prior therapy subgroup is 
likely to be lower than £49,848 per QALY gained. Ibrutinib was recommended as an option for 
treating R/R MCL in adults, only if they have had only one previous line of therapy and the 
company provides ibrutinib with the discount agreed in the commercial access agreement with 
NHS England.  
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1. INTRODUCTION 
Health technologies must be shown to be clinically effective and to represent a cost-effective use of 
resources to be recommended for use within the National Health Service (NHS) in England. The 
National Institute for Health and Care Excellence (NICE) is an independent organisation responsible 
for providing national guidance on promoting good health, and preventing and treating ill health, in 
priority areas with significant impact. The NICE Single Technology Appraisal (STA) process usually 
covers new technologies soon after they have received UK marketing authorisation and is specifically 
designed for the appraisal of a single health technology within a single indication [1]. Within the STA 
process, the manufacturer of a technology provides NICE with a written submission containing relevant 
clinical effectiveness evidence alongside a health economic model that summarises the FRPSDQ\¶V
estimates of the cost-effectiveness of the technology. The Evidence Review Group (ERG), an external 
academic organisation which is independent of NICE, reviews the submission with advice from clinical 
specialists and produces an ERG report. The NICE appraisal committee $&FRQVLGHUVWKHFRPSDQ\¶V
submission (CS), the ERG report, and testimony from experts and other stakeholders and formulates 
preliminary guidance - the appraisal consultation document (ACD) - which indicates the initial decision 
of the AC regarding the recommendation (or not) of the intervention. Stakeholders are subsequently 
invited to comment on the submitted evidence and the ACD, after which an ACD may be produced or 
a final appraisal determination (FAD) issued, which is open to appeal. An ACD is not produced when 
the intervention is recommended without restriction; in such instances, a FAD is produced directly. This 
paper presents a summary of the ERG report produced by the School of Health and Related Research 
Technology Assessment Group at the University of Sheffield [2] and the NICE FAD [3] for the STA 
of ibrutinib for the treatment of patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). 
It also covers the subsequent development of the NICE guidance for the use of this drug in England [4]. 
Full details of all relevant appraisal documents can be found on the NICE website [5].  
 
2. THE DECISION PROBLEM 
MCL is a B-cell malignancy with unique biological, pathological and clinical features, which comprises 
approximately 3-10% of all non-Hodgkin lymphomas (NHLs). MCL typically arises in older adults, 
with a median age of presentation of between 60 and 65 years of age. Approximately 75% of patients 
with MCL are male. The disease is rare: the company estimated that there would be 356 patients with 
R/R MCL in England, Wales and Northern Ireland in 2017 [6]. MCL is characterised by an aggressive 
clinical disease course, but features a pattern of resistant and relapsing disease, thereby rendering it 
incurable with standard therapy. The prognosis for patients with MCL is very poor compared with other 
forms of NHL; after excluding patients for whom autologous stem cell transplantation (ASCT) is a 
treatment option, median survival for patients with MCL following first relapse is typically reported to 
be approximately 1-2 years [7], but may be lower.  
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2.1 Current treatment 
There is no standard of care for patients with R/R MCL and the disease remains very difficult to manage. 
The British Committee for Standards in Haematology (BCSH) guidelines [7] note that the choice of 
therapy at relapse will be determined by patient age, performance status, bone marrow reserve, initial 
therapy and history of infections. For patients who have not received transplantation as first-line 
therapy, but are sufficiently fit for such therapy following relapse, ASCT may be considered as a clinical 
option [7]. However, this is not a common scenario as most patients who are suitable for an autograft 
will have received it first-line when it is best tolerated and likely to be most effective. For older and/or 
less fit patients, a range of systemic chemotherapy regimens may be considered, provided the patient is 
sufficiently fit to receive them. Treatment typically involves chemotherapy with or without rituximab 
and may include regimens such as: R-CHOP (rituximab, cyclophosphamide, doxorubicin and 
vincristine); R-bendamustine (rituximab and bendamustine); FCR (rituximab, fludarabine and 
cyclophosphamide); R-CVP (rituximab, cyclophosphamide, vincristine and prednisolone), or R-
chlorambucil (rituximab and chlorambucil). None of these therapies are specifically licensed for the 
treatment of R/R MCL. Guidelines published by the European Society for Medical Oncology (ESMO) 
discourage the use of R-CVP and FCR due to inferior response rates and long-lasting myelosuppression 
[8]. The BCSH guidelines for MCL report that several other regimens have been shown to have activity 
in R/R MCL, including: (i) bortezomib; (ii) bortezomib-gemcitabine; (iii) bortezomib-rituximab; (iv) 
temsirolimus (TEM); (v) rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM); (vi) 
fludarabine; (vii) fludarabine-cyclophosphamide; (viii) fludarabine-cyclophosphamide+/-rituximab; 
(ix) cladribine; (x) gemcitabine-dexamethasone; (xi) gemcitabine-dexamethasone-cisplatin; (xii) 
lenalidomide; (xiii) thalidomide-rituximab, and (xiv) prednisone, etoposide, procarbazine, and 
cyclophosphamide (PEP-C)/thalidomide/rituximab [7]. Where patients have received one previous line 
of treatment, a different regimen would typically be used following relapse. Whilst ESMO recommends 
targeted therapies such as TEM, bortezomib and lenalidomide [8], TEM is not currently used in 
England, bortezomib is recommended only in untreated MCL and lenalidomide is available only via a 
compassionate use programme [6].  
 
In February 2016, NICE issued a final scope to appraise the clinical effectiveness and cost-effectiveness 
of ibrutinib for the treatment of R/R MCL [9]. 
 
3. INDEPENDENT ERG REVIEW 
The company (Janssen) provided a submission to NICE on the clinical effectiveness and cost-
effectiveness of ibrutinib for the treatment of R/R MCL [6]. This submission was critically appraised 
by the ERG. Subsequently, the ERG identified areas requiring clarification, for which the company 
provided additional evidence prior to completion of the ERG report [10].  
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3.1 Clinical evidence submitted by the company 
Clinical effectiveness data were taken from three studies, comprising one randomised controlled trial 
(RCT) (RAY [MCL3001]) and two single-arm studies (PCYC1104 and SPARK [MCL2001]) [11-13]. 
One additional study RI7(0YHUVXVSK\VLFLDQV¶FKRLFHRI WKHUDS\ (the OPTIMAL study [14]) was 
included in an indirect comparison of ibrutinib versus single-agent chemotherapy. 
 
At the time of the CS, median OS had not been reached in the ibrutinib arm of the RAY study (n=139) 
or in the SPARK study (n=120). In Study PCYC1104 (n=111), median OS was 22.5 months.  
  
Median PFS for ibrutinib-treated patients was 14.6 months in the RAY study, 13.0 months in the final 
analysis of Study PCYC1104, and 10.5 months in the SPARK study. In the RAY study, median PFS 
within the TEM arm was 6.2 months; this was significantly worse than for the ibrutinib arm (hazard 
ratio [HR]=0.43, 95% confidence interval [CI] 0.32 to 0.58; p<0.0001). Overall response rates (ORR) 
assessed by independent review committee (IRC) were similar for ibrutinib-treated patients across 
studies (71.9% in RAY, 69% in Study PCYC1104 and 62.7% in SPARK). In RAY, there was a 
significant advantage in overall response rate (ORR) for ibrutinib over TEM (ORR=40.4%, odds ratio 
[OR]=3.98, 95% CI 2.38 to 6.65; difference in ORR p<0.0001). 
 
Health-related quality of life (HRQoL) was measured by Functional Assessment of Cancer Therapy - 
Lymphoma (FACT-Lym) in the RAY (MCL3001) and SPARK (MCL2001) studies [15]. In the RAY 
study, 61.9% of ibrutinib-treated patients reported a clinically meaningful improvement; significantly 
fewer TEM-treated patients reported clinically meaningful improvement (35.5%, p<0.0001).   
 
Across the three studies of ibrutinib (RAY, SPARK and PCYC1104), the most common adverse events 
(AEs) for ibrutinib RISDWLHQWVZHUH: diarrhoea; cough; fatigue; thrombocytopenia; neutropenia; 
peripheral oedema; nausea; muscle spasms, and pyrexia. 
 
7KH FRPSDQ\¶V LQGLUHFW FRPSDULVRQ of ibrutinib versus single-agent chemotherapy suggested that 
ibrutinib is associated with a slower rate of disease progression compared with single-agent 
chemotherapy (HR=0.19, 95% CI 0.10, 0.36) and a survival benefit (HR=0.61, 95% CI 0.34, 1.10), 
although the result for OS is inconclusive as it did not reach statistical significance at the 95% level. 
Rituximab is used in routine clinical practice in England, therefore to account for the differential 
effectiveness of using rituximab alongside chemotherapy, the company performed an additional 
adjustment to the HR for PFS. The adjusted HR for PFS for ibrutinib versus R-chemo was estimated to 
be 0.28. 
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3.2 Critique of clinical effectiveness evidence and interpretation 
The ERG believed that all relevant studies had been included in the CS [6]. The studies presented were 
relevant to the population, intervention and outcomes of the decision problem. The CS did not identify 
any RCTs which included head-to-head comparisons of ibrutinib versus any of the comparators listed 
in the final NICE scope [9]. TEM, the comparator in the RAY trial, is not used in UK practice. 
 
The populations of the three included ibrutinib studies reflect the demographic characteristics of the 
R/R MCL population that would be eligible for treatment using ibrutinib in England. However, in 
practice, patients may have more comorbidities than those included in the studies. The studies were 
international, with a small proportion of patients from the UK, thus there may be differences between 
the treatment pathways of the patients enrolled into the ibrutinib studies and those seen in current 
practice in England. 
 
One of the included ibrutinib studies was an RCT (RAY), whereas the other two studies (SPARK and 
PCYC1104) adopted a single-arm design. All three included ibrutinib studies were open-label and 
therefore were subject to potential bias. However, all studies addressed the issue of measurement bias 
for the primary outcome by having an assessment of the primary outcome by IRC. All three studies 
were sufficiently large to be adequately powered for their primary endpoint of PFS (RAY) or ORR 
(PCYC1104 and SPARK). OS was not adequately powered, and may have been influenced by the 
differential use of subsequent therapies between treatment groups. The TEM arm in the RAY study had 
better outcomes than the TEM arm in the OPTIMAL study. There is uncertainty regarding how much 
of this difference is due to TEM treatment, differences in populations between trials and routine 
practice, and the use of other therapies, or random chance. 
 
The company adopted a two-stage approach to estimate treatment effects for ibrutinib versus R-chemo. 
The ERG considers that a single-stage random effects NMA would provide a better representation of 
the uncertainty in the resulting treatment comparisons. Based on additional analyses undertaken by the 
ERG, ibrutinib is associated with a slower rate of disease progression, compared to R-chemo, but with 
considerable uncertainty (random effects HR=0.27, 95% credible interval [CrI] 0.06 to 1.26). The 
estimated median HRs for OS for ibrutinib versus R-chemo ranged from 0.98 to 1.96, depending on the 
data source used for the rituximab arm of the network (an RCT reported by Forstpointner et al [16], 
audit data from the Haematological Malignancy Research Network [HMRN] [17], or both). Due to 
concerns regarding the evidence used to inform the indirect comparisons, the ERG advised that the 
results of the indirect comparison should be interpreted with caution. 
 
 
 
8 
 
3.3 Cost-effectiveness evidence submitted by the company 
The company submitted a de novo health economic model which assessed the cost-effectiveness of 
ibrutinib versus R-CHOP (rituximab, cyclophosphamide, vincristine and prednisolone) for the 
treatment of patients with R/R MCL over a 15-year (lifetime) horizon from the perspective of the UK 
NHS and Personal Social Services (PSS). Costs and health outcomes were discounted at a rate of 3.5% 
per annum. Unit costs were valued at 2014/15 prices. Separate subgroup analyses were presented for 
patients who have received one prior line of therapy (LOT) and for patients who have received SULRU
LOTs. At the time of the appraisal, a Patient Access Scheme (PAS) in the form of a simple price 
discount had been agreed with the Department of Health. The value of this discount changed over the 
course of the appraisal. The level of the PAS is confidential; all cost-effectiveness results presented here 
are based on the original PAS, unless otherwise stated. 
 
The coPSDQ\¶VEDVHFDVHPRGHOLQFOXGHG three health states: (i) progression-free; (ii) post-progression, 
and; (iii) dead. The model also implicitly included a further separation between patients who are 
progression-free and on treatment and those who are progression-free after treatment discontinuation. 
The model adopted a 28-day cycle length. Within the ibrutinib group, health state transitions were 
modelled using parametric survivor functions fitted to data on pre-progression-mortality (exponential 
model), PFS (Weibull model), and post-progression survival (PPS, exponential model) from a pooled 
dataset of the RAY, SPARK and PCYC1104 studies [18]. Time to treatment discontinuation or death 
(TTD/D) was also modelled using a parametric survivor function (Weibull model), but did not impact 
on transitions between health states. The benefits of ibrutinib versus R-CHOP were modelled using the 
FRPSDQ\¶VLQGLUHFWFRPSDULVRQXVLQJWKHRAY trial [19] (ibrutinib versus TEM), the OPTIMAL trial 
[14] (TEM vHUVXVSK\VLFLDQ¶VFKRLFHof single-agent chemotherapy) and audit data from the HMRN 
[17] (R-chemo versus chemotherapy alone). This HR was applied to both the PFS and TTD/D curves 
for ibrutinib. The PPS curves for both groups were based on the pooled ibrutinib dataset [18]. Health 
utilities for the progression-free and post-progression states were derived from EQ-5D-5L data collected 
within the RAY and SPARK studies [19, 20]; the model also included a disutility associated with R-
chemo toxicity which was based on clinical opinion. Health utilities were age-adjusted. 7KHFRPSDQ\¶V
model included costs associated with drug acquisition, drug administration, follow-up, management of 
AEs, best supportive care (BSC) and death. Other resource use, including imaging, tests, biopsies, 
transfusions and hospitalisations, was estimated from a survey of NHS haematologists and oncologists 
[6]. Unit costs were taken from the Monthly Index of Medical Specialties (MIMs) [21], the Commercial 
Medicines Unit (CMU) electronic market information tool (eMit) [22] and NHS Reference Costs [23]. 
 
Based on a re-UXQ RI WKHSUREDELOLVWLF YHUVLRQ RI WKH FRPSDQ\¶V EDVH FDVH PRGHO E\ WKH (5* WKH
incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-CHOP was expected to be £76,014 
per quality-adjusted life year (QALY) gained. The deterministic model produced similar results 
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(ICER=£75,317 per QALY gained). Assuming a willingness-to-pay (WTP) threshold of £50,000 per 
QALY gained, the coPSDQ\¶VEDVHFDVHPRGHOVXJJHVWHG that the probability that ibrutinib produces 
more net benefit than R-CHOP was approximately zero. $FURVVDOOEXWRQHRIWKHFRPSDQ\¶VVFHQDULR
analyses, the ICER for ibrutinib versus R-chemo was greater than £70,000 per QALY gained. The only 
exception to this related to an analysis in which the PPS rate for R-chemo was ³FDOLEUDWHG´VXFKWKDW
the overall modelled OS for R-CHOP was equal to the 8.4 month OS estimate reported within the 
HMRN audit [17] (ICER=£59,345 per QALY gained). However, it should be noted that this was an 
analysis in the one prior LOT subgroup rather than the overall population. 
 
3.3.1 Critique of cost-effectiveness evidence and interpretation 
7KH (5* FULWLFDOO\ DSSUDLVHG WKH FRPSDQ\¶V HFRQRPLF DQDO\VLV and double-programmed the 
GHWHUPLQLVWLFYHUVLRQRIWKHFRPSDQ\¶VPRGHOThe main issues identified by the ERG are discussed 
below; the full critique can be found in the ERG report [2]. 
 
3.3.1.1 Modelling approach 
7KHFRPSDQ\¶V0DUNRYmodel used three sets of transition probabilities derived from time-to-event 
data: (i) progression-free to dead (pre-progression mortality); (ii) progression-free to post-progression 
(calculated using PFS adjusted for pre-progression mortality), and; (iii) post-progression to dead (PPS). 
Whilst Markov models are commonly used in many areas of evaluation, the ERG had three main 
concerns with the FRPSDQ\¶Vapproach: (a) the hazard of pre-progression mortality was assumed to be 
constant over time; (b) the use of PPS data includes only those patients who have progressed and thus 
may be subject to selection bias, and (c) the model included a structural assumption that PPS was 
exponentially distributed. Furthermore, because the same PPS curve was used for both treatment 
groups, this use of evidence within a Markov framework imposes a direct surrogate relationship 
between PFS gains and OS gains, whereby if the same pre-progression mortality curve is assumed for 
both groups, the incremental gain in PFS leads to an equivalent incremental gain in OS. The ERG had 
concerns that this assumption may not be reasonable and was not adequately supported by evidence. 
Overall, the ERG noted that the precise modelling approach adopted is not important provided that the 
selected model structure does not impose inappropriate restrictions on the synthesis of evidence and the 
model-predicted outcomes are credible. However, tKHFRPSDQ\¶VPRGHO-predicted OS did not provide 
a good visual fit to the observed Kaplan-Meier curve for ibrutinib: rather, the model over-estimated the 
OS for ibrutinib up to around 15.6 months and subsequently under-predicted OS beyond this timepoint 
(Figure 1). This suggested that the modelled OS trajectory for the ibrutinib group had likely been 
underestimated. No equivalent data were available for the R-chemo group of the model, hence the 
accuracy of the OS prediction in this group is unknown. As a consequence of these issues, the ERG had 
concerns regarding WKH FUHGLELOLW\ RI WKH FRPSDQ\¶V results. The ERG noted that an alternative 
modelling approach, for example, the partitioned survival approach applied in a previous model of 
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ibrutinib for MCL [24], would have allowed for the inclusion of the available OS data for ibrutinib 
within the model and may have produced more robust predictions. 
 
Figure 1: Comparison of observed and predicted overall survival for ibrutinib group 
[INSERT FIGURE 1 HERE] 
 
3.3.1.2 Issues surrounding use of parametric survival modelling 
The ERG highlighted several concerns UHJDUGLQJWKHFRPSDQ\¶VSDUDPHWULFsurvival modelling of data 
on pre-progression-mortality, PFS, and PPS. Within the CS [6], only a limited set of candidate survivor 
functions (exponential, Weibull, log normal and log logistic) were fitted to the available PFS data for 
ibrutinib. Other survivor functions, for example, the Gompertz, the generalised gamma, the gamma and 
the generalised F models should have been considered. Following clarification, the company fitted 
Gompertz and generalised gamma functions to the PFS data, but noted that both produced clinically 
implausible projections [10]. In addition, within the CS, both pre-progression mortality and PPS were 
assumed to be subject to a constant hazard rate. Following clarification, the company provided some 
evidence that the exponential model provided a reasonable fit to the pre-progression mortality data. The 
company also subsequently fitted alternative parametric functions to the PPS data [10], however, given 
that the model included a structural assumption that the PPS hazard is constant, these alternative 
functions could not be incorporated into the model, hence their impact on the ICER is unknown. 
 
3.3.1.3 Methods for modelling time to treatment discontinuation (or death) 
The company fitted exponential, Weibull, log logistic and log normal survivor functions to data on 
TTD/D from the pooled ibrutinib dataset [6]; the Weibull model was selected for use in the base case 
analysis. However, all fitted curves considerably overestimated the probability of being alive and on 
treatment beyond the final observed datapoint within the ibrutinib dataset. Based on the FRPSDQ\¶V
fitted Weibull model, the probability that a patient would still be receiving treatment at 50 months was 
approximately 7%, whilst the Kaplan-Meier curve indicated that all patients had discontinued by around 
32 months. Consequently, the modelled drug costs for ibrutinib, and therefore the ICER, were 
overestimated. The ERG considered that whilst the Kaplan-Meier curve is most uncertain in its tail, the 
best estimate of the cumulative survival probability for TTD/D would be obtained from the observed 
Kaplan-Meier curve rather than a parametric model which does not provide a good fit to those data. The 
ERG also noted that if censoring was truly random, additional data collection over a longer follow-up 
should not produce a systematic shift in the Kaplan-Meier curve.  
 
3.3.1.4 Uncertainty surrounding relative effectiveness of ibrutinib versus currently used treatments  
Given the absence of any head-to-head trials of ibrutinib versus R-chemo in patients with R/R MCL, 
the FRPSDQ\¶Veconomic analysis was hinged on an indirect comparison informed by the RAY study 
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[19], the OPTIMAL trial [14] and the HMRN audit [17]. ERG highlighted a number of limitations and 
uncertainties in WKHFRPSDQ\¶VLQGLUHFWFRPSDULVRQ 
x The treatment effect for ibrutinib versus R-chemo, and the associated uncertainty around this 
estimate, could have been more meaningfully synthesised using a random effects NMA. 
x The OPTIMAL trial [14] involved only single-agent chemotherapy, however, with the 
exception of cytarabine, all options included in the final NICE scope relate to combination 
chemotherapy regimens [9]. 
x The HR for PFS taken from the HMRN audit did not specifically relate to patients with R/R 
disease, did not differentiate between chemotherapy regimens, and reflected only those patients 
achieving response [17]. In addition, since this study is not an RCT, the HR may be subject to 
confounding due to differences in patient characteristics. 
x 7KH(5*¶VFlinical advisors suggested that rituximab plus bendamustine (R-bendamustine), 
rather than R-CHOP, is likely to represent the main comparator for ibrutinib, although other R-
chemo regimens may be considered and clinical outcomes for R-bendamustine and R-CHOP 
are likely to be similar.  
x Pre-progression mortality for patients receiving R-chemo is not included as an outcome in the 
indirect comparison, but is instead assumed to be equal to the rate observed in the TEM arm of 
the RAY trial [19]. Given the absence of evidence, the validity of this assumption is unclear. 
x The indirect comparison used in the health economic model is restricted to the outcome of PFS. 
The ERG noted that the HR for OS for R-chemo versus chemotherapy could have instead been 
derived using data from the RCT reported by Forstpointner et al [16].  
 
In light of these issues, the ERG noted that any estimate of treatment effect for ibrutinib relative to R-
chemo derived from the available evidence base will be subject to considerable uncertainty. 
 
3.3.1.5 Additional concerns identified by the ERG 
The ERG noted a number of other concerns UHJDUGLQJ WKH FRPSDQ\¶V HFRQRPLF DQDO\VLV 7KHVH
included: (i) the inappropriate exclusion of costs of subsequent therapies beyond progression; (ii) the 
use of blended comparison of R-chemo options with equal efficacy; (iii) an assumption of an HRQoL 
decrement associated with R-chemo for patients which is sustained beyond discontinuation, and (iv) 
uncertainty and risk of confounding in the FRPSDQ\¶VVXEJURXSDQDO\VHV based on number of LOTs.  
 
3.4 Additional work undertaken by the ERG 
The ERG undertook two sets of exploratory analyses ± ³6HW$´DQG³6HW%´. Exploratory analysis Set 
A was XQGHUWDNHQXVLQJWKHFRPSDQ\¶VMarkov PRGHO7KH(5*¶Vpreferred analysis involved using 
WKH+5IRU3)6GHULYHGIURP(5*¶V random effects NMA, applying the observed Kaplan-Meier curve 
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for TTD/D for the ibrutinib group, and truncating the R-chemo disutility following treatment 
discontinuation. Based on this scenario, the probabilistic ICER for ibrutinib versus R-CHOP was 
£63,340 per QALY gained (Table 1). The ICERs for all other analyses based on this ERG-preferred 
model were greater than £59,952 per QALY gained. Within the one prior LOT subgroup, the ICER for 
ibrutinib versus R-CHOP was estimated to be £44,711 per QALY gained.  
 
Exploratory analysis Set B involved converting WKHFRPSDQ\¶VPRGHOVWUXFWXUHto adopt a partitioned 
survival approach. This entailed using the available data for PFS and OS for ibrutinib from the pooled 
dataset and the estimation of treatment effects on PFS and OS GHULYHGIURPWKH(5*¶VNMAs. These 
analyses suggested that irrespective of whether the rituximab effect is estimated using data reported by 
Forstpointner et al [16], the HRMN audit [17], or both, ibrutinib is expected to be dominated. 
Importantly, the ERG noted that this economic conclusion was likely to be a consequence of problems 
in robustly estimating treatment effects for OS given the weaknesses in the available evidence.  
 
3.5 Conclusion of the ERG report 
As R/R MCL is a relatively rare disease, few real-world data are available. Only three studies of 
ibrutinib in R/R MCL patients were identified, and these did not reflect treatment pathways relevant to 
current clinical practice in England. %DVHGRQWKH(5*¶VDGGLWLRQDODQDO\VHV LEUXWLQLE LVDVVRFLDWHG
with a slower rate of disease progression compared with R-chemo (random effects HR=0.27, 95% CrI 
0.06 to 1.26), although the result is inconclusive as it did not reach statistical significance at the 95% 
level. The estimated median HRs for OS for ibrutinib versus R-chemo ranged from 0.98 to 1.96, 
depending on the data source used for the rituximab arm of the network. This illustrates the high level 
of uncertainty for this comparison. %DVHGRQDQDO\VHVRIWKHFRPSDQ\¶VPRGHOXQGHUWDNHQE\WKH(5* 
LQFOXGLQJWKHFRPSDQ\¶VRULJLQDO3$6), the ICER for ibrutinib versus R-chemo is likely to be greater 
than £59,952 per QALY gained in the overall R/R MCL population. The cost-effectiveness profile of 
ibrutinib appears to be improved in the one prior LOT subgroup, but may be subject to confounding 
due to the post hoc definition of the subgroup and bias due to the poor fit of the Weibull function used 
to model PFS. 
 
4. METHODOLOGICAL ISSUES 
The ERG noted problems relating to the robustness of the indirect comparison for OS. The ERG 
FRQVLGHUV WKDWDEDODQFHH[LVWV LQWKDW WKHFRPSDQ\¶V3)6-based Markov model makes a number of 
restrictive structural assumptions which lead to a poor model fit to the available OS data for ibrutinib, 
ZKLOVWWKH(5*¶VSDUWLWLRQHGVXUYLYDODQDO\VLVexploratory analysis Set B) provided a better fit to the 
OS data but involved using the outputs of a highly uncertain NMA. 
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5. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) GUIDANCE 
The appraisal committee reviewed the data available on the clinical and cost effectiveness of ibrutinib, 
having considered evidence on the nature of R/R MCL and the value placed on the benefits of ibrutinib 
by people with the condition, those who represent them, and clinical experts. It also took into account 
the effective use of NHS resources. 
 
The first ACD (published August 2016) did not recommend ibrutinib within its marketing authorisation 
for the treatment of adult patients with R/R MCL [25]. The AC noted that the ICERs presented by the 
company, which incorporated the original PAS for ibrutinib, were substantially above the range 
normally considered a cost-effective use of NHS resources. Following the first ACD, the company 
submitted an additional analysis of the HMRN dataset and updated the PAS for ibrutinib. The AC 
FRQVLGHUHG WKDW WKLV QHZ DQDO\VLV SURYLGHG VRPH UHDVVXUDQFH UHJDUGLQJ WKH FRPSDQ\¶V PRGHOOLQJ 
method, but noted that the ICER was higher than the committee could accept as a cost-effective use of 
NHS resources. 
 
Following the second ACD, the company submitted a response which included a newer data-cut from 
the RAY study and requested routine commissioning for ibrutinib within the one prior LOT subgroup, 
based on an ICER of £49,849 per QALY gained. In December 2017, NICE published its FAD [3], 
which made the following recommendation: ³,EUXWLQLE LV UHFRPPHQGHG DV DQ RSWLRQ IRU WUHDWLQJ
relapsed or refractory mantle cell lymphoma in adults, only if: 
x they have had only 1 previous line of therapy and  
x the company provides ibrutinib with the discount agreed in the commercial access agreement 
ZLWK1+6(QJODQG´ 
 
5.1 Consideration of clinical effectiveness and cost-effectiveness issues 
This section discusses the key issues considered by the AC. The full list can be found in the FAD [3]. 
 
5.1.1 Clinical trial evidence 
The AC noted that the evidence on the clinical effectiveness of ibrutinib came from one RCT (RAY) 
and two single-arm studies (SPARK and PCYC-1104). It considered that RAY is not strictly relevant 
to NHS practice because TEM is not routinely used in the UK and noted the absence of trials comparing 
ibrutinib with any comparator defined in the NICE scope. The committee concluded that the studies 
were of a reasonable quality but were limited by the lack of a comparison against a treatment used in 
UK clinical practice. The committee noted that at median follow-up of 20 months in RAY, median PFS 
was statistically significantly longer for ibrutinib compared with TEM (14.6 months compared with 6.2 
months; HR=0.43; 95% CI 0.32 to 0.58; p<0.0001). At the time of the first AC meeting, the OS data 
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from RAY were immature and median OS had not yet been reached in the ibrutinib arm. The committee 
understood that the OS results could be confounded as 23% of patients in the TEM arm switched to 
subsequently receive ibrutinib and the use of subsequent anticancer systemic therapies differed between 
treatment groups. Following consultation on the second ACD, the committee considered updated data 
from RAY provided by the company; they noted that that the updated results were consistent with the 
earlier data and that median OS had now been reached (30.3 months for ibrutinib compared with 23.5 
months for TEM; HR=0.74; 95% CI 0.54 to 1.02). The committee concluded that the results from RAY 
suggest that ibrutinib significantly improves PFS compared with TEM, but that the OS benefits remain 
uncertain. 
 
5.1.2 Indirect comparison 
The committee understood WKHFRPSDQ\¶VLQGLUHFWFRPSDULVRQXVLQJGDWDIURP5$<237,0$/and 
the HMRN audit resulted in an HR for PFS for ibrutinib versus R-chemo of 0.28. The committee 
acknowledged the limitations of the indirect comparison and noted that the ERG did not agree with the 
company's two-stage approach to estimating treatment effects. The committee noted that because of 
concerns about the evidence used to inform the indirect comparisons, the ERG considered that the 
results of both WKHFRPSDQ\¶VDQDO\VHVDQGWKH(5*¶Vanalyses should be interpreted with caution. The 
committee concluded that there is considerable uncertainty associated with the indirect comparisons 
and that the benefit of ibrutinib compared with R-chemo is unclear, although it accepted that the 
available evidence and experience from clinical practice strongly suggest that ibrutinib is more 
effective. 
 
5.1.3 Subgroups 
The committee discussed the efficacy results for subgroups of patients, based on the number of previous 
LOTs. It noted that the results suggest greater efficacy in patients who had ibrutinib after only one 
previous LOT, compared with two or more previous LOTs. The clinical expert also stated that ibrutinib 
is particularly beneficial after the first relapse. The committee considered the updated RAY data and 
noted that these provide further evidence of a greater benefit of ibrutinib when taken after only one 
previous LOT. The committee understood that the data were potentially confounded by patients in the 
TEM arm switching to ibrutinib and that the subgroups were defined post hoc. However, the committee 
noted responses to the ACD from professional groups that stated that evidence from clinical practice 
supports the RAY results, and that earlier use of ibrutinib in R/R disease is the most beneficial. The 
committee concluded that the evidence from RAY and clinical experience suggests that ibrutinib is 
most effective in people who have had only one previous LOT. 
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5.1.4 &RPSDQ\¶VHFRQRPLFanalysis 
The committee noted that the company had developed a Markov model comparing ibrutinib with R-
chemo, comprising three states (pre-progression, post-progression and death), and that this approach 
had been used in previous appraisals. The committee was aware that OS data from the ibrutinib studies 
were not directly extrapolated but were modelled using PFS and PPS data from the pooled ibrutinib 
GDWDVHW7KHFRPPLWWHHFRQVLGHUHGWKDWWKHFRPSDQ\¶VDSSURDFKLVDSSURSULDWHJLYHQWKHLPPDWXULW\RI
the OS data available.  
 
7KHFRPPLWWHHFRQVLGHUHGWKH(5*¶VFULWLTXHRIWKHFRPSDQ\¶VPRGHO,WQRWHGWKH(5*¶VFRPPHQWV
that the comSDQ\¶V0DUNRYDSSURDFKLPSRVHGVWUXFWXUDOFRQVWUDLQWVZKLFKGLGQRWPDNHWKHEHVWXVH
of the trial data on survival, and that the OS predicted by the model did not provide a good visual fit to 
the observed Kaplan-Meier OS curve from the trials. The committee understood that the ERG had 
explored the effect of using a partitioned survival approach in their exploratory analysis (Set B), but 
was concerned that this resulted in efficacy estimates for R-chemo that were higher than those for 
ibrutinib, giving higher QALY gains for R-chemo than ibrutinib which were implausible. The 
committee concluded that the results of the partitioned survival analysis were not clinically plausible, 
DFNQRZOHGJLQJWKH(5*¶VFRPPHQWVWKDWWKH\DUHDVVRFLDWHGZLWKPDMRUXQFHUWDLQW\because they rely 
on the outputs of a highly uncertain meta-analysis. 
 
The committee re-H[DPLQHGWKHFRPSDQ\¶V0DUNRYDSSURDFKZKLFKLWFRQVLGHUHGOHGWRPRUHSODXVLEOH
UHVXOWV7KHFRPPLWWHHQRWHGWKDWLQWKHFRPSDQ\¶VEDVH-case analysis which incorporated the updated 
PAS, the ICER for ibrutinib versus R-chemo was £62,650 per QALY gained. The committee also noted 
that DOOEXWRQHRIWKHFRPSDQ\¶VVFHQDULRDQDO\VHVSURGXFHGICERs which were above £59,000 per 
QALY gained. In this one scenario, the company applied an HR to post-progression survival for R-
chemo, which was adjusted to be as close as possible to the anticipated survival based on the results of 
the HMRN audit. This resulted in an ICER of £49,849 per QALY gained. However, the committee 
understood that time-to-event estimates for PFS and PPS for ibrutinib were taken from the one prior 
LOT subgroup, and therefore that the analysis reflects this subgroup. 
 
The FRPPLWWHHQRWHGWKDWWKH(5*¶VH[SORUDWRU\DQDO\VHVXVLQJWKHFRPSDQ\¶VPRGHO6HW$made 
DGMXVWPHQWVWRVRPHRIWKHSDUDPHWHUYDOXHVLQWKHFRPSDQ\¶VPRGHO which mostly resulted in lower 
ICERs than those presented by the company. However, the committee was minded not to accept the 
UHVXOWVRIWKH(5*¶Vpreferred base case for Set A because these represented the extreme (lowest) end 
RI WKH(5*¶VZLGH HVWLPDWHRISRVVLEOH ,&(5VGHSHQGLQJRQ WKHPRGHO DQGSDUDPHWHUVXVHG7KH
committee concluded that the ICERs presented by the company for the whole population of people with 
R/R MCL, incorporating the updated PAS for ibrutinib, were above the range normally considered a 
cost-effective use of NHS resources (£20,000 to £30,000 per QALY gained). The committee recognised 
16 
 
that ibrutinib has several benefits which may not be reflected in the QALY calculations (oral 
administration, manageable adverse reactions and low toxicity); however, it did not consider that these 
would be sufficient to lower the ICER for the whole population to within the range normally considered 
to be cost-effective. 
 
Noting its conclusion that trial evidence and clinical experience suggest that ibrutinib is most effective 
in people who have had only one prior LOT, the committee considered whether ibrutinib could be 
considered cost-effective in this subgroup of patients. It noted that WKHFRPSDQ\¶V,&(5RISHU
QALY gained may be a conservative estimate because updated trial data from RAY suggest that the 
model underestimates survival for this subgroup. The committee also noted that overall survival in RAY 
may have been confounded by the switching of patients in the TEM arm to the ibrutinib arm. The 
committee concluded that the most plausible ICER in this group of patients is likely to be lower than 
WKHFRPSDQ\¶VHVWLPDWHRISHU4$/<JDLQHG  
 
The committee noted that the OS estimates presented for people with R/R MCL ranged from 5.2 months 
to 9.7 months. It also accepted that there is enough evidence to indicate that ibrutinib offers an extension 
to life of at least an additional 3 months, compared with current NHS treatment. On this basis, the 
committee concluded that ibrutinib met all the criteria to be considered a life-extending end-of-life 
treatment. 
 
$335$,6$/&200,77((¶6.(<&21&/86,21 
The committee concluded that the most plausible ICER for the one prior LOT subgroup is likely to be 
ORZHUWKDQWKHFRPSDQ\¶VHVWLPDWHRISHU4$/<JDLQHG 
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Figure 1: Comparison of observed and predicted overall survival for ibrutinib group 
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Table 1: Summary of key results from the CS and the ERG report (using the original PAS for 
ibrutinib in the MCL indication) 
Scenario ICER (per 
QALY gained) 
Ibrutinib versus 
R-chemo 
&RPSDQ\¶VHFRQRPLFDQDO\VLV 
&RPSDQ\¶VEDVHFDVHSUREDELOLVWLF £76,014 
&RPSDQ\¶VPRVWIDYRXUDEOH'6$Assuming R-chemo post-progression 
mortality probability = 0.27 (to reflect HMRN median OS of 8.4 months) 
using the 1 prior LOT subgroup) 
£59,345 
&RPSDQ\¶VOHDVWIDYRXUDEOH'6$3)6PRGHOOHGXVLQJH[SRQHQWLDO
distribution) 
£80,296 
Subgroup analysis ± 1 prior LOT subgroup £65,977 
ERG exploratory analyses, Set A ± EDVHGRQWKHFRPSDQ\¶V0DUNRYPRGHO 
ERG explRUDWRU\DQDO\VLV$+5IRU3)6GHULYHGIURP(5*¶VUDQGRPHIIHFWV
NMA 
£75,094 
ERG exploratory analysis A2: TTD/D for ibrutinib group based on Kaplan-
Meier curve 
£61,472 
ERG exploratory analysis A3: Truncation of R-chemo disutility following 
treatment discontinuation 
£77,111 
([SORUDWRU\DQDO\VLV$(5*¶VSUHIHUUHGDQDO\VLVXVLQJWKHFRPSDQ\¶VPRGHO
(combining ERG analyses A1, A2 and A3, probabilistic) 
£63,340 
Exploratory analysis A5i: Utilities for progression-free and post-progression 
based on Lachaine et al[26]EDVHGRQWKH(5*¶VSUHIHUUHGDQDO\VLV 
£60,417 
Exploratory analysis A5ii: Utilities for progression-free and post-progression 
based on Yoong et al[27]EDVHGRQWKH(5*¶VSUHIHUUHGDQDO\VLV 
£59,952 
Exploratory analysis A6i: Cost-effectiveness of ibrutinib versus chemotherapy 
for rituximab-resistant patients (rituximab cost set equal to zero), based on the 
(5*¶VSUHIHUUHGDQDO\VLV 
£69,054 
Exploratory analysis A6ii: Cost-effectiveness of ibrutinib versus chemotherapy 
for rituximab-resistant patients  (Cost of rituximab set to zero and PFS 
HR=0.19), based on the ER*¶VSUHIHUUHGDQDO\VLV 
£64,727 
Exploratory analysis A7: Ibrutinib versus R-CHOP in the 1 prior LOT subgroup 
XVLQJWKH(5*¶VSUHIHUUHGDQDO\VLVEDVHGRQWKH(5*¶VSUHIHUUHGDQDO\VLV 
£44,711 
ERG exploratory analyses, Set B ± EDVHGRQWKH(5*¶s partitioned survival model and NMAs 
for PFS and OS 
Rituximab effect informed by Forstpointner et al[16] Dominated 
NMA rituximab effect informed by HMRN[17] Dominated 
NMA rituximab effect informed by Forstpointner et al[17] Dominated 
 
ICER ± incremental cost-effectiveness ratio; QALY ± quality-adjusted life year; DSA ± deterministic sensitivity analysis; 
HMRN ± Haematological Malignancy Research Network; LOT ± line of therapy; HR ± hazard ratio; OS ± overall survival; 
PFS ± progression-free survival; TTD/D ± time to treatment discontinuation or death; R-CHOP - rituximab, 
cyclophosphamide, doxorubicin and vincristine; NMA ± network meta-analysis; ERG ± Evidence Review Group 
 
 
